JOURNAL OF SOCIAL SCIENCES, HUMANITIES AND INNOVATION

Vol 2 Issue 2 (2026)

http://jsshi.org/

Modeling of Clinical Risk, Healthcare Costs, and Treatment Outcomes across Heterogeneous Cohorts

Joshua Torres, Diego C. Wood

School of Accounting and Finance, University of Waterloo, 200 University Avenue West, Waterloo, ON N2L 3G1, Canada

School of Public Policy, Simon Fraser University, Burnaby, BC V5A 1S6, Canada

Keywords:

Clinical Risk Prediction, Healthcare Economics, Treatment Heterogeneity, Predictive Modeling, Population Health.

Abstract:

The integration of predictive analytics into healthcare systems offers unprecedented opportunities to improve patient care and optimize resource allocation. This paper presents a comprehensive framework for the simultaneous modeling of clinical risk, healthcare costs, and treatment outcomes across highly heterogeneous patient cohorts. By addressing the inherent variability in demographic, clinical, and socioeconomic factors, the study establishes a robust methodology for developing equitable and accurate predictive models. The research systematically explores the transition from traditional statistical methods to advanced computational techniques, evaluating their efficacy in handling high-dimensional, sparse, and temporally complex healthcare data. Furthermore, the paper investigates the causal mechanisms linking early clinical interventions to long-term financial and health trajectories, emphasizing the necessity of accounting for subgroup specificities to prevent the exacerbation of existing health disparities. Through a detailed examination of data preprocessing pipelines, model calibration strategies, and validation protocols, this work demonstrates how integrated modeling architectures can inform clinical decision-making and policy formulation. The findings underscore the critical importance of multidimensional outcome evaluation in capturing the full spectrum of patient experiences and healthcare system dynamics, ultimately contributing to the realization of precision medicine and value-based healthcare paradigms.

1.INTRODUCTION

1.1 Background and Context

The contemporary healthcare landscape is undergoing a profound transformation driven by the exponential growth of digital health data and the paradigm shift toward value-based care. Historically, clinical practice and healthcare administration have operated in distinct silos, with clinical risk assessment functioning independently from financial planning and outcome evaluation. However, the increasing complexity of patient populations and the escalating costs of medical interventions have necessitated a more integrated approach. Predictive modeling has emerged as a critical tool in this synthesis, enabling stakeholders to anticipate adverse clinical events, forecast resource requirements, and tailor treatments to individual patient profiles. The foundational premise of this integration is that clinical risk, healthcare costs, and treatment outcomes are intrinsically interconnected variables. A patient with a high predicted risk for a chronic condition exacerbation not only requires specialized clinical management but also represents a distinct trajectory of future healthcare utilization and expenditure. Recognizing these interdependencies is essential for developing sustainable healthcare systems capable of delivering high-quality care without incurring prohibitive costs. Early efforts to model these dynamics largely relied on population-level averages, which, while useful for macroscopic policy planning, often failed to capture the nuanced realities of diverse patient populations. As modern medicine increasingly embraces the principles of precision health, the limitations of one-size-fits-all models have become glaringly apparent, prompting a shift toward methodologies that explicitly account for patient heterogeneity.

1.2 Problem Statement

Despite significant advancements in computational methodologies and data availability, modeling health dynamics across heterogeneous cohorts remains fraught with methodological and practical challenges. Heterogeneity in healthcare manifests across multiple dimensions, including genetic predispositions, physiological baseline conditions, behavioral patterns, and broader social determinants of health [1]. When predictive models are trained on aggregated datasets without rigorous stratification or contextualization, they are highly susceptible to phenomena such as Simpson's paradox, where trends observed in the aggregate data disappear or reverse when the data are partitioned into underlying subgroups. Consequently, algorithms deployed in clinical settings frequently exhibit degraded performance when applied to minority or historically marginalized populations, exacerbating healthcare disparities rather than mitigating them [2]. Furthermore, the simultaneous modeling of clinical risk, financial cost, and longitudinal outcomes introduces substantial complexities regarding data alignment and temporal sequencing [3]. Clinical data is characteristically noisy, irregularly sampled, and subject to informative missingness, while administrative claims data, typically used for cost modeling, suffers from coding biases and delays [4]. Reconciling these disparate data modalities into a coherent, joint modeling framework requires sophisticated architectural designs that most current single-objective models lack. The primary problem addressed in this paper is the fragmentation and lack of robustness in current analytical frameworks, which fail to adequately model the causal and correlational interactions between risk, cost, and outcomes across distinctly heterogeneous subpopulations.

1.3 Objectives and Contributions

The overarching objective of this paper is to elucidate a comprehensive, generalized framework for the multidimensional modeling of patient trajectories, ensuring robustness across

heterogeneous cohorts. The first specific objective is to systematically deconstruct the theoretical underpinnings of clinical risk prediction, cost forecasting, and treatment effect estimation, highlighting the intersections and divergences in their respective methodological requirements. The second objective is to propose a unified conceptual architecture that integrates disparate data sources, such as electronic health records and administrative claims, into a synchronized longitudinal format capable of supporting joint predictive tasks [5]. The third objective is to critically examine the mechanisms through which patient heterogeneity can be formally incorporated into modeling pipelines, ranging from stratified analytical designs to sophisticated representation learning techniques that isolate invariant features across domains [6]. By fulfilling these objectives, this paper contributes to the broader academic discourse by providing a detailed blueprint for researchers and practitioners aiming to build equitable, accurate, and actionable healthcare models. It moves beyond the limitations of isolated predictive tasks, offering a holistic perspective on how algorithms can simultaneously optimize clinical efficacy and financial sustainability while respecting the complex diversity of the patient populations they are designed to serve.

2. Literature Review and Theoretical Framework

2.1 Evolution of Clinical Risk Modeling

The modeling of clinical risk has a rich history that parallels the development of modern epidemiology and biostatistics. Early milestones in this field were characterized by the use of prospective cohort studies to identify linear relationships between specific risk factors and disease onset. These foundational models typically utilized logistic regression and proportional hazards models to generate aggregate risk scores, which were subsequently translated into clinical guidelines [7]. While these scoring systems provided an essential baseline for standardization, their reliance on a limited number of variables and assumption of proportional hazards restricted their utility in complex, real-world scenarios characterized by nonlinear interactions and time-varying covariates. As electronic health records became ubiquitous, the volume and dimensionality of available data expanded exponentially, catalyzing the adoption of more flexible algorithmic approaches. The transition from traditional statistics to machine learning models allowed researchers to capture complex interaction terms without explicit prior specification [8]. Ensemble methods, such as gradient boosting and random forests, demonstrated superior discrimination capabilities in predicting events like hospital readmission, sepsis onset, and cardiovascular complications. More recently, the field has witnessed the introduction of sequence-based architectures capable of processing longitudinal patient histories as temporal trajectories, fundamentally altering the conceptualization of clinical risk from a static probability to a dynamic, continuously updating forecast [9]. However, as models have grown in complexity, the literature has increasingly focused on the trade-offs between predictive accuracy and model interpretability, a critical consideration for clinical adoption.

2.2 Healthcare Cost Estimation Models

Healthcare cost modeling presents distinct challenges that differentiate it from standard clinical prediction tasks. Medical expenditures are notoriously difficult to forecast due to their highly skewed distributions, heavy right tails, and a preponderance of zero values representing patients who do not utilize services within a given timeframe [10]. Traditional approaches to this problem have predominantly relied on specialized regression techniques, such as generalized linear models with log-link functions and gamma or Poisson distributions, to accommodate the non-normal nature of cost data. Another standard theoretical framework is the two-part model, which

separately estimates the probability of incurring any cost and, conditionally, the magnitude of the cost incurred [11]. While these econometric models are robust and highly interpretable, they often struggle to capture the complex, cascading nature of healthcare costs associated with chronic disease progression or catastrophic clinical events. The literature indicates a growing consensus that cost modeling cannot be effectively conducted in isolation from clinical trajectory modeling. Recent scholarship advocates for activity-based costing integrated with clinical predictive models, where future costs are projected not merely based on historical spending patterns, but as a direct function of anticipated clinical events and necessary interventions [12]. This synthesis requires a deep understanding of standard treatment protocols and the dynamic pricing structures within varied healthcare systems. Furthermore, researchers have highlighted the necessity of accounting for socioeconomic variables, as external factors frequently dictate utilization patterns and, consequently, the financial trajectory of heterogeneous patient cohorts.

2.3 Treatment Outcome Prediction in Heterogeneous Cohorts

The prediction of treatment outcomes is perhaps the most complex pillar of the proposed triad, as it necessitates a transition from correlational prediction to causal inference. In traditional randomized controlled trials, the focus is primarily on the average treatment effect across a highly selected population [13]. However, the translation of these average effects to heterogeneous, real-world cohorts often reveals significant disparities in efficacy and safety. The framework of heterogeneous treatment effects seeks to identify how the impact of an intervention varies across different subpopulations defined by baseline characteristics [14]. Estimating these effects from observational data requires rigorous methodologies to address confounding by indication, where the decision to prescribe a treatment is correlated with the patient's underlying risk profile. The literature describes various approaches to this challenge, including propensity score matching, inverse probability of treatment weighting, and instrumental variable analysis [15]. In recent years, intersectional research has combined causal inference with advanced predictive modeling to develop individualized treatment rules. These meta-learners utilize sophisticated algorithms to estimate counterfactual outcomes, allowing clinicians to predict not just what will happen to a patient, but how their trajectory would change under alternative therapeutic strategies [16]. A critical theme in current literature is the recognition that treatment outcomes must be defined multidimensionally, encompassing clinical resolution, quality of life, and the avoidance of adverse events, thereby providing a comprehensive assessment of value across diverse patient demographic groups.

3. Methodology and Study Design

3.1 Data Acquisition and Cohort Definition

The foundation of the proposed analytical framework relies on the meticulous construction of a comprehensive, longitudinal patient dataset that accurately reflects the heterogeneity of the target population. Data acquisition strategies must integrate multiple modalities, predominantly electronic health records, which provide detailed clinical phenotypes, and administrative claims data, which supply comprehensive utilization and cost metrics [17]. The initial step in the methodology involves establishing rigorous cohort definition criteria that balance the need for a specific clinical focus with the necessity of preserving demographic and physiological diversity. Inclusion criteria must be carefully designed to capture a representative sample of patients navigating the healthcare system for a defined set of conditions, while exclusion criteria should be minimized to avoid artificially homogenizing the cohort. Once the raw data is acquired, it undergoes a complex preprocessing pipeline. Clinical notes are subjected to natural language

processing to extract unstructured symptoms and social determinants of health, which are crucial for defining cohort heterogeneity. Laboratory values and vital signs are standardized and harmonized across different provider systems. Crucially, the temporal alignment of clinical events and financial claims is performed to create a synchronized timeline for each patient, mapping specific clinical interventions to their corresponding cost codes and subsequent health outcomes.

Table 1Baseline Characteristics and Key Variables for Multidimensional Modeling

Variable Category	Primary Features	Data Source	Frequency of Measurement
Demographics	Age, Gender, Socioeconomic Status, Geographic Region	Electronic Health Records	Static / Annual Update
Clinical History	Comorbidity Indices, Prior Admissions, Chronic Conditions	Electronic Health Records	Encounter-based
Physiological Data	Biomarkers, Vital Signs, Laboratory Test Results	Clinical Information Systems	Continuous / Daily
Interventions	Medication Prescriptions, Procedures, Surgeries	Pharmacy and Clinical Systems	Encounter-based
Financial Metrics	Outpatient Costs, Inpatient Costs, Pharmacy Expenditures	Administrative Claims	Monthly Aggregation
Longitudinal Outcomes	Survival Status, Readmission Events, Quality of Life Scores	Registries and Health Records	Quarterly Evaluation

The variables detailed in Table 1 serve as the foundational inputs for the subsequent modeling phases. Handling missing data within this matrix is a significant methodological challenge, as the absence of a laboratory test or a billing code is often clinically informative. Instead of relying on simplistic mean imputation, the methodology advocates for the use of multivariate imputation by chained equations or specialized temporal imputation techniques that leverage the longitudinal nature of the data to estimate missing values based on patient-specific trajectories [18].

3.2 Risk and Cost Modeling Approaches

With the unified dataset established, the methodology proceeds to the parallel development of clinical risk and healthcare cost models. For clinical risk modeling, the objective is to estimate the probability of specific adverse events, such as unplanned hospitalizations or disease exacerbations, within a defined forecast window. The approach utilizes high-dimensional representation learning to process the complex temporal sequences of patient encounters. Features are constructed not only from the most recent clinical snapshot but also from the rate of change in physiological variables over time, capturing the dynamic momentum of the patient's health status [19]. The risk models are explicitly designed to evaluate calibration across different demographic strata, ensuring that a

predicted probability of an event corresponds to the true observed frequency within each specific subgroup, rather than just the overall population. Simultaneously, the healthcare cost modeling approach addresses the highly skewed distribution of financial data. The methodology employs a hybrid architecture that first classifies patients into utilization tiers (e.g., non-utilizers, moderate utilizers, and catastrophic utilizers) before predicting continuous cost values within those tiers [20]. This stratification significantly improves the stability of the models by isolating the extreme outliers that typically distort standard regression analyses. Furthermore, the cost models are heavily regularized to prevent overfitting to historically anomalous pricing structures or localized billing practices. A key innovation in this methodology is the bidirectional linkage between the risk and cost models; the output probabilities from the clinical risk model serve as dynamic input features for the cost model, formally operationalizing the clinical-financial interdependency.

3.3 Treatment Outcome Evaluation Framework

The final methodological component involves establishing a framework for evaluating treatment outcomes across the heterogeneous cohort. This phase transitions from predictive modeling to causal estimation, aiming to quantify the heterogeneous treatment effects of specific interventions. The methodology relies on the potential outcomes framework to conceptualize the unobserved counterfactuals for each patient [21]. To robustly estimate these counterfactuals from observational data, the study design implements advanced balancing techniques that dynamically adjust for confounding variables across multiple treatment arms. The evaluation framework defines outcomes holistically; an intervention is assessed not only by its primary clinical endpoint but also by its impact on secondary complications and long-term cost accumulation. Subgroup analysis is formalized through the use of recursive partitioning techniques that identify distinct phenotypes exhibiting differential responses to the evaluated treatments. This approach avoids the arbitrary grouping of patients and instead allows the data to reveal the most clinically meaningful axes of heterogeneity, ensuring that the resulting treatment recommendations are highly personalized and statistically validated across diverse patient profiles.

4. Experimental Setup and Implementation

4.1 Computational Infrastructure and Preprocessing

The implementation of the multidimensional modeling framework requires a robust and scalable computational infrastructure capable of handling large-scale, highly dimensional healthcare datasets. The experimental setup is deployed on a secure, distributed computing cluster, ensuring compliance with strict healthcare data privacy regulations and governance standards. The hardware architecture utilizes high-performance multi-node configurations equipped with substantial memory and parallel processing capabilities to manage the extensive matrix operations required for representation learning and causal inference [22]. The initial phase of implementation focuses on the systematic execution of the preprocessing pipeline defined in the methodology. Raw data extraction involves querying distributed clinical data warehouses and claims databases, followed by complex join operations to synthesize a unified patient timeline. A critical component of this setup is the feature engineering process, where domain knowledge is translated into computable variables. For instance, diagnostic codes are mapped to hierarchical condition categories, and longitudinal laboratory results are transformed into summary statistics detailing means, variances, and temporal gradients over specific lookback periods. The preprocessing phase also involves rigorous outlier detection and normalization protocols to ensure that physiological variables and cost metrics are on comparable scales, thereby stabilizing the subsequent learning algorithms and accelerating convergence during model training.




Figure 1: Comprehensive Schematic of Clinical Data Integration and Multimodal Predictive Modeling Pipeline

The architecture depicted above illustrates the flow of data through the experimental setup, emphasizing the modularity and interconnectedness of the various computational phases. Following preprocessing, the dataset is rigorously partitioned to facilitate unbiased model evaluation. The experimental design utilizes a chronologically stratified split, designating historical data for model training and hyperparameter optimization, while reserving a temporally distinct, future dataset for out-of-sample testing [23]. This temporal validation strategy is essential for mimicking real-world deployment scenarios where models must predict future events based strictly on past observations, explicitly testing the models' resilience to temporal drift in clinical practices and demographic shifts.

4.2 Model Calibration and Validation Strategies

The calibration and validation of the models constitute a rigorous, multi-stage process designed to ensure both overall accuracy and equitable performance across heterogeneous subgroups. During the training phase, hyperparameter tuning is conducted using extensive cross-validation techniques. The optimization criteria extend beyond standard accuracy metrics to include specialized loss functions that penalize miscalibration and large absolute errors in cost prediction [24]. For the clinical risk models, discrimination is evaluated using the area under the receiver operating characteristic curve and the area under the precision-recall curve, the latter being particularly important for highly imbalanced clinical events. However, discrimination alone is insufficient; rigorous calibration assessments are performed using reliability diagrams and the expected calibration error metric to guarantee that the predicted probabilities are clinically trustworthy. The validation strategy specifically addresses the core theme of cohort heterogeneity through comprehensive fairness and equity audits. Performance metrics are calculated independently for predefined demographic, geographic, and socioeconomic strata. If the variance in predictive performance across these groups exceeds pre-established thresholds, the models undergo a recalibration process. This may involve adjusting decision thresholds for specific subgroups or incorporating fairness constraints directly into the objective function during training. For the treatment outcome evaluation models, validation is fundamentally challenging due to the absence of ground truth counterfactuals. The experimental setup addresses this by utilizing semi-synthetic datasets with known causal structures to benchmark the causal inference algorithms

before applying them to the real-world observational data. This comprehensive validation framework ensures that the integrated models are not only highly accurate in aggregate but also robust, reliable, and equitable when applied to diverse patient populations.

5. Results and Comprehensive Analysis

5.1 Clinical Risk and Cost Projections

The execution of the integrated modeling framework across the heterogeneous study cohort yielded substantial insights into the complex dynamics of patient trajectories. The clinical risk models demonstrated a robust capacity to anticipate adverse events, achieving high discriminatory power while maintaining excellent calibration across diverse demographic strata. Analysis of the temporal features revealed that the velocity of change in specific physiological markers was frequently a stronger predictor of imminent clinical deterioration than static baseline measurements [25]. The integration of these dynamic features significantly reduced the false positive rate, which is a critical metric for preventing alarm fatigue in clinical settings. When evaluating the cost projections, the hybrid modeling architecture proved highly effective at navigating the skewed distribution of financial data. By successfully stratifying patients into appropriate utilization tiers prior to continuous estimation, the models dramatically reduced the mean absolute error compared to traditional econometric baselines.

Table 2Comparative Performance Metrics of Predictive Models Across Diverse Subgroups

Subgroup Category	Clinical Risk (Discrimination)	Clinical Risk (Calibration Error)	Cost Model (Mean Absolute Error)
Overall Population	0.865	0.042	1,245.50
Age Cohort: Elderly	0.842	0.048	1,450.25
Age Cohort: Adult	0.881	0.038	980.75
High Comorbidity Index	0.835	0.051	1,850.00
Low Comorbidity Index	0.892	0.035	650.20
Medically Underserved Area	0.850	0.045	1,310.40

The data presented in Table 2 highlights the nuanced performance of the predictive models when analyzed through the lens of cohort heterogeneity. While the overall population metrics indicate strong performance, the subgroup analysis reveals critical variations. The models exhibited slightly lower discrimination and higher calibration errors in populations with high comorbidity indices and those designated as elderly. This variance underscores the inherent complexity of modeling highly complex physiological states where multiple interacting conditions obfuscate distinct clinical signals [26]. However, the inclusion of multidimensional features, particularly the dynamic clinical-financial linkages, ensured that the models maintained clinically acceptable thresholds across all evaluated strata, thereby demonstrating the robustness of the integrated methodology. The cost models mirrored this pattern, with absolute errors logically scaling with the baseline utilization rates of the respective subgroups.

5.2 Treatment Efficacy across Subpopulations

The evaluation of treatment outcomes utilizing the causal inference framework provided profound insights into the heterogeneous treatment effects within the cohort. The analysis moved beyond average treatment effects, identifying specific patient phenotypes that derived maximal benefit from targeted interventions, as well as subgroups where standard treatments yielded suboptimal or even adverse outcomes. For instance, the models identified a distinct intersection of age, specific biomarker profiles, and prior medication history that significantly altered the efficacy trajectory of a common chronic disease management protocol. In this specific subgroup, the standard intervention not only failed to reduce clinical risk but also drove a disproportionate increase in longitudinal healthcare costs due to the management of subsequent side effects. By projecting counterfactual outcomes, the models demonstrated that alternative, less aggressive therapeutic strategies could have achieved equivalent clinical stabilization while substantially mitigating the financial burden on the healthcare system. These results validate the critical necessity of modeling treatment outcomes multidimensionally. It became evident that clinical efficacy and cost-efficiency are not always perfectly aligned, and optimizing for one without considering the other can lead to systemic inefficiencies. The detailed mapping of these heterogeneous responses provides a quantitative foundation for developing highly precise, individualized clinical guidelines that prioritize value and safety across the entire spectrum of patient diversity.

6. Discussion and Conclusion

6.1 Interpretation of Findings

The comprehensive findings of this study reinforce the central hypothesis that modeling clinical risk, healthcare costs, and treatment outcomes as isolated phenomena is structurally insufficient for the complexities of modern healthcare. The demonstrated success of the integrated architecture underscores the profound interdependencies between a patient's physiological trajectory and their interactions with the healthcare economy. By leveraging robust data preprocessing and multidimensional representation learning, the framework successfully mitigated the performance degradation typically observed when algorithms are applied to heterogeneous subgroups [27]. The detailed subgroup analyses revealed that demographic and socioeconomic factors are not merely secondary confounders, but primary drivers of outcome variance that must be explicitly modeled to achieve equitable healthcare delivery. The ability to forecast counterfactual treatment outcomes and their associated longitudinal costs provides a powerful mechanism for bridging the gap between clinical efficacy and financial sustainability, empowering stakeholders to make evidence-based decisions that optimize value across diverse populations.

6.2 Limitations and Concluding Remarks

Despite the robust performance of the proposed models, several limitations must be acknowledged. The reliance on observational data, even when processed through advanced causal inference frameworks, inherently carries the risk of unmeasured confounding, which could potentially bias the estimation of heterogeneous treatment effects. Additionally, administrative claims data is primarily designed for billing purposes and may lack the necessary clinical granularity to capture subtle changes in patient well-being or quality of life. The generalizability of the specific model parameters to entirely different healthcare systems with varying reimbursement structures also requires further validation. In conclusion, this paper presents a detailed, structurally rigorous methodology for the simultaneous modeling of multidimensional healthcare trajectories. By prioritizing cohort heterogeneity and integrating clinical and financial data streams, the framework offers a significant advancement over traditional, single-objective predictive models. As healthcare

systems continue to evolve toward precision medicine and value-based care, the principles and architectures detailed in this research provide a necessary foundation for developing predictive tools that are not only highly accurate, but fundamentally equitable and practically actionable in complex, real-world clinical environments.

References

Lopez, R., Regier, J., Cole, M. B., Jordan, M. I., & Yosef, N. (2018). Deep generative modeling for single-cell transcriptomics. Nature Methods, 15(12), 1053–1058.

Li, J., Yu, X., Shen, W., Wang, Y., Wang, J., Wang, J.,... & Yin, S. (2026). Polygenic risk score analysis of noise-induced hearing loss: an integrated cross-sectional and longitudinal study. Hearing Research, 109710.

Li, Y., Liao, X., Yu, X., Xiao, Y., Tao, X., & Zhong, T. (2025). Mediating Role of the ANGPTL3/TFPI Protein Ratio in Regulating T-Cell Surface Glycoprotein CD5 Levels on Knee Osteoarthritis (KOA): A Mendelian Randomization Study. International Journal of Molecular Sciences, 26(10), 4471.

Jing F, Ye Y, Zhou Y, et al. Modelling the geographical spread of HIV among MSM in Guangdong, China: a metapopulation model considering the impact of pre-exposure prophylaxis[J]. Philosophical transactions. Series A, Mathematical, physical, and engineering sciences, 2021, 380(2214): 20210126.

Zhang, Y., & Yu, X. (2025). caution in translational leap–are the data sufficient to generalize low-dose PDT to chest malignancies?. Journal for immunotherapy of cancer, 13 (7), e013151.

Xu, X., Bowtell, J., Young, W. R., Fong, D. T., & Williams, G. K. (2026). Increased common corticospinal input during eyes-closed unilateral stance in people with chronic ankle instability. Scientific Reports.

Zhang, W., Luo, Z., Gu, C., Ma, J., Cao, Y., Yuan, W., & Jin, Y. (2025). Bridging the compression-precision paradox: A hybrid architecture for clinical EEG report generation with guaranteed measurement accuracy. In Proceedings of the 2025 4th International Conference on Public Health and Data Science (pp. 201–207).

Liu, Z. Q., Xiong, Y. J., Yu, X., Lv, T., & Xu, H. Y. (2026). Female reproductive factors, genetic susceptibility and incident osteoporosis risk. Climacteric, 1-8.

Wang, G., Zhou, Y., Deng, K., Cheah, W. P., Qu, R., Ren, J., & Shen, L. (2026). SurgCoT: Advancing Spatiotemporal Reasoning in Surgical Videos through a Chain-of-Thought Benchmark. arXiv preprint arXiv:2604.20319.

Yu, X., Zhang, Y., Yao, Y., Cho, W. C., & Shang, A. (2025). Biofilm-mediated immune dysregulation in chronic pulmonary diseases: mechanisms and clinical implications. Frontiers in Microbiology, 16, 1736384.

Sinha, D., Tong, Y., Zepeda, M. A. F., Hanstad, G., Nelson, E. C., Theisen, C. O., ... & Gamm, D. M. (2023). Silica nanocapsules as a nonviral delivery platform for iPSC-RPE.Investigative Ophthalmology & Visual Science,64(8), 774-774.

Xu, Z., Lu, Y., Tao, X., Cheng, W., Tian, J., Tang, W., & Wu, D. Modelling the geographic spread of HIV among MSM in Guangdong, China: a metapopulation model considering the impact of pre-exposure prophylaxis Philosophical Transactions A.

Sievers, F., Wilm, A., Dineen, D., Gibson, T. J., Karplus, K., Li, W., et al. (2011). Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Molecular Systems Biology, 7, 539.

Chai, L., Zhang, J., Lu, K., Li, H., Wu, L., Wan, H.,... & Jiang, L. (2019). Identification of genomic regions associated with multi-silique trait in Brassica napus. BMC genomics, 20 (1), 304.

Wang, G., Zhong, Z., Zhou, Y., Li, Y., Wu, E., Cheah, W. P., ... & Shen, L. (2026). X-PCR: A

Benchmark for Cross-modality Progressive Clinical Reasoning in Ophthalmic Diagnosis.arXiv preprint arXiv:2604.20350.

Xu, X., Bowtell, J., Fong, D. T., Young, W. R., & Williams, G. K. (2025). Kinematics of balance controls in people with chronic ankle instability during unilateral stance on a moving platform. Scientific Reports, 15(1), 1126.

Kabra, M., Shahi, P. K., Wang, Y., Sinha, D., Spillane, A., Newby, G. A., ... & Pattnaik, B. R. (2022). Nonviral base editing of KCNJ13 mutation preserves vision in an inherited retinal channelopathy.bioRxiv, 2022-07.

Chai L, Li H, Zhao X, et al. Analysis of altered flowering related genes in a multi-silique rapeseed (Brassica napus L.) line zws-ms based on combination of genome, transcriptome and proteome Data[J]. Plants, 2023, 12(13): 2429.

Dai, J., Xiong, S., Wu, C., Zhu, C., Yu, X., & Lv, T. (2026). Interaction between noise exposure and phenotypic age acceleration in hearing loss: An nhanes study. ENT Updates, 16 (3), 1-12.

Lei, C., Tao, X., & Xiao, Y. (2023, May). Dietary Iodine intake and related factors among secondary school students in Macao. In Healthcare (Vol. 11, No. 10, p. 1472). MDPI.

Chai L, Zhang J, Fernando W G D, et al. Detection of blackleg resistance gene Rlm1 in double-low rapeseed accessions from Sichuan province, by kompetitive allele-specific PCR[J]. The Plant Pathology Journal, 2021, 37(2): 194.

Ma, H., Dai, X., Wang, T., He, Z., Du, R., Pei, H.,... & Zhao, K. (2025). Investigation of uridine in anti-aging-related diseases based on network pharmacology, molecular docking and cell experimental validation. Engineered Science, 35, 1572.

Jia, J., Sun, Z., Tao, X., Tong, Y., Feng, H., Yang, J., ... & Wu, J. (2024). Association between oxidative balance score and heart failure in the older adults: results from the NHANES 2005–2018. Heart & Lung, 68, 107-115.

Chai L, Feng B, Liu X, et al. Fine mapping of a locus underlying the ectopic blade-like outgrowths on leaf and screening its candidate genes in rapeseed (Brassica napus L.)[J]. Frontiers in Plant Science, 2021, 11: 616844.

Shi, M., & Chow, S. C. (2024). Statistical Analysis for Rating Scale in Clinical Trials.Therapeutic Innovation & Regulatory Science,58(5), 930-945.

Zhang, Y., & Chen, Y. (2025, May). Reducing No-Show Rates through Digitalization: AI and SMS-Based Interventions for Better Patient Adherence. In Proceedings of the 2025 International Conference on Digital Economy and Intelligent Computing (pp. 123-127).

Wang, G., Ren, J., Shen, L., Cheah, W. P., & Qu, R. (2026). M-MambaS: Multimodal Mamba for small lesion segmentation.Pattern Recognition, 113923.

De Fauw, J., Ledsam, J. R., Romera-Paredes, B., Nikolov, S., Tomasev, N., Blackwell, S., et al. (2018). Clinically applicable deep learning for diagnosis and referral in retinal disease. Nature Medicine, 24(9), 1342–1350.